Strategic Forecast for the Live Attenuated Vaccines Industry: Market Outlook 2025-2034

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Live Attenuated Vaccines Market Size Growth Forecast: What to Expect by 2025?
The market for live attenuated vaccines has experienced swift expansion in the past few years. Expected to escalate from $23.58 billion in 2024 to $25.95 billion in 2025, it will exhibit a compound annual growth rate (CAGR) of 10.1%. The amplification during the historical timeframe is attributed to the increased worldwide immunization coverage, amplified public health expenditure, heightened consciousness about disease prevention, escalated demand for pediatric vaccines, and broadening of vaccination initiatives.

How Will the Live Attenuated Vaccines Market Size Evolve and Grow by 2029?
The market for live attenuated vaccines is anticipated to experience robust expansion in the coming years, reaching $37.56 billion by 2029, with a compound annual growth rate (CAGR) of 9.7%. This growth predicted in the forthcoming period is due to the increased focus on proactive health care, rising acceptance in low- to middle-income nations, enhanced efforts towards outbreak readiness, a surge in travel-related immunization requirements, and broadening of government-backed immunization endeavors. Key trends forecasted in the same period include progress in vaccine delivery mechanisms, novel genetic attenuation procedure innovations, investment surge in research and development, emergence of thermostable formulations, and digital technology innovations in immunization schemes.

View the full report here:
https://www.thebusinessresearchcompany.com/report/live-attenuated-vaccines-global-market-report

What Drivers Are Propelling the Growth of Live Attenuated Vaccines Market Forward?
The expansion of the live attenuated vaccines market is set to be driven by the growing incidences of infectious diseases. These diseases, originating from dangerous microorganisms such as bacteria, viruses, fungi, or parasites, can transmit directly or indirectly from individuals, animals, or the environment. The speeding up of global travel has inadvertently encouraged the quick spread of infectious diseases as it permits pathogens to cross national boundaries faster than containment attempts. Live attenuated vaccines play a vital role in preventing these diseases by eliciting a robust immune response with weakened pathogens, paving for long-term immunity and controlling disease transmission. For example, data from the World Health Organization, a Switzerland-based intergovernmental organization, shows that in 2023 about 10.8 million people globally had TB, which included 6.0 million men, 3.6 million women, and 1.3 million children. This escalation in the prevalence of infectious diseases underscores the driving factor behind the growth of the live attenuated vaccines market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24590&type=smp

Which Emerging Trends Are Transforming the Live Attenuated Vaccines Market in 2025?
Leading firms in the live attenuated vaccines market have shifted their focus towards the creation of advanced products, like single-dose vaccines, in order to maximize immunization effectiveness and increase patient compliance. The beauty of single-dose vaccines lies in their ability to offer enduring immunity with just one shot, thereby negating the necessity for multiple doses. This not only simplifies the vaccination process for patients and healthcare providers but also amplifies convenience and availability. In an instance from November 2023, Valneva SE, a French biotech entity that specializes in the production of vaccines for infectious diseases, proclaimed the introduction of IXCHIQ. This product received the green light from the U.S. Food and Drug Administration (FDA), a health agency based in the U.S. Interestingly, it is the first-ever live-attenuated chikungunya vaccine suitable for adults 18 and above. The clearance of IXCHIQ is monumental since it stands as the globe's initial approved vaccine for chikungunya. This addresses a critical healthcare gap for protection against this mosquito-inspired viral illness, characterized by intense fever, muscular and joint pain, among other symptoms.

What Are the Key Segments in the Live Attenuated Vaccines Market?
The live attenuated vaccines market covered in this report is segmented -

1) By Vaccine Type: Monovalent, Multivalent
2) By Route Of Administration: Intramuscular, Subcutaneous, Oral Attenuated, Intranasal Attenuated
3) By Indication: Influenza, Measles, Mumps and Rubella (MMR), Polio, Chickenpox, Shingles, Rotavirus, Other Indications
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
5) By End-User: Hospitals, Clinics, Diagnostic Centers, Research Institute, Other End-Users

Subsegments:
1) By Monovalent: Single-Dose Vaccines, Multiple-Dose Vaccines
2) By Multivalent: Bivalent Vaccines, Trivalent Vaccines, Quadrivalent Vaccines, Other Multivalent Vaccines

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=24590&type=smp

Who Are the Key Players Shaping the Live Attenuated Vaccines Market's Competitive Landscape?
Major companies operating in the live attenuated vaccines market are Merck & Co. Inc., Sanofi SA, AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, CSL Limited, GC Biopharma, Serum Institute of India Pvt. Ltd., Bavarian Nordic, Valneva SE, Southern Research, BioFarma, Bharat Biotech International Limited, Meissa Vaccines Inc., BioDiem Ltd., Bio-Med Limited, Naobios, Lakshmi Pharmaceuticals

What Geographic Markets Are Powering Growth in the Live Attenuated Vaccines Market?
North America was the largest region in the live attenuated vaccines market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the live attenuated vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24590

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.